logo-loader
AIM:MXCT

MaxCyte Inc

Receive alerts
Market:
AIM
Market Cap:
£183.8 m
Price
238.00 GBX
Change
-0.83%
52 weeks high
242.00
52 weeks low
95.00

In brief

We are a U.S.-based global company driving the acceleration of the discovery/development, manufacturing and commercialization of next-generation, cell-based medicines.

Deep dive We explore the investor case for growth companies

Snapshot

  • Pioneering work in gene editing to tackle cancer
  • "Highly optimistic" during coronavirus crisis
  • Over 100 cell therapy licences with partners, including 11 at the clinical stage

 

Insight Widest with the analysis, Proactive gives perspectives that others don't.

Nkarta's explosive flotation shows the market's interest for cell therapies

Tiziana Life Sciences and MaxCyte are two London-listed stocks to watch in the space

2 hours, 52 minutes ago